Peter D. Senter
Impact in
- Radiology, Nuclear Medicine and Imaging top 0.05%
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Biomaterials top 0.2%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Monoclonal and Polyclonal Antibodies Research 81
- Radiopharmaceutical Chemistry and Applications 5
- Immunology 31
- Toxin Mechanisms and Immunotoxins 25
- Co-authors
- Eric L. Sievers (3 shared papers)Anna M. Wu (1 shared paper)Stephen C. Alley (11 shared papers)Damon L. Meyer (18 shared papers)Nicole M. Okeley (13 shared papers)Svetlana O. Doronina (18 shared papers)Charles G. Cerveny (15 shared papers)Alan F. Wahl (12 shared papers)
- Journals
- Bioconjugate Chemistry (19 papers)Cancer Research (10 papers)Molecular Cancer Therapeutics (9 papers)Blood (7 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesGermanyBelgium
In The Last Decade
Peter D. Senter
115 papers receiving 14.2k citations
Peter D. Senter's Hit Papers
Peers
Comparison fields: 5 of 117
- Radiology, Nuclear Medicine and Imaging 7.5k
- Biomaterials 2k
- Immunology 2.3k
- Oncology 1.4k
- Organic Chemistry 1.9k
Countries citing papers authored by Peter D. Senter
This map shows the geographic impact of Peter D. Senter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter D. Senter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter D. Senter more than expected).
Fields of papers citing papers by Peter D. Senter
This network shows the impact of papers produced by Peter D. Senter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter D. Senter. The network helps show where Peter D. Senter may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter D. Senter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 118 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Hit paper breakdown → | 2004 | 1052 |
| 2 | Development of potent monoclonal antibody auristatin conjugates for cancer therapy Hit paper breakdown → | 2003 | 1030 |
| 3 | Arming antibodies: prospects and challenges for immunoconjugates Hit paper breakdown → | 2005 | 886 |
| 4 | cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Hit paper breakdown → | 2003 | 770 |
| 5 | Antibody-Drug Conjugates in Cancer Therapy Hit paper breakdown → | 2012 | 665 |
| 6 | The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Hit paper breakdown → | 2012 | 662 |
| 7 | Antibody–drug conjugates come of age in oncology Hit paper breakdown → | 2023 | 629 |
| 8 | Antibody–drug conjugates: targeted drug delivery for cancer Hit paper breakdown → | 2010 | 567 |
| 9 | Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index Hit paper breakdown → | 2015 | 467 |
| 10 | 2005 | 446 | |
| 11 | Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates Hit paper breakdown → | 2008 | 410 |
| 12 | Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates Hit paper breakdown → | 2014 | 409 |
| 13 | 2008 | 357 | |
| 14 | 2007 | 345 | |
| 15 | 2013 | 336 | |
| 16 | 2009 | 334 | |
| 17 | 2010 | 333 | |
| 18 | 2005 | 325 | |
| 19 | 2004 | 317 | |
| 20 | 2005 | 243 |
About Peter D. Senter
Peter D. Senter is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology, Organic Chemistry, Oncology and Biomaterials, having authored 118 papers that have together received 15.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (81 papers), Toxin Mechanisms and Immunotoxins (25 papers), Synthesis and pharmacology of benzodiazepine derivatives (13 papers), Chemical Synthesis and Analysis (8 papers), Nanoparticle-Based Drug Delivery (8 papers), Synthesis and biological activity (8 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Cancer therapeutics and mechanisms (5 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (7.5k citations), Biomaterials (2k citations), Immunology (2.3k citations), Oncology (1.4k citations) and Organic Chemistry (1.9k citations). Peter D. Senter has collaborated with scholars based in United States, Germany and Belgium. Frequent co-authors include Eric L. Sievers, Anna M. Wu, Stephen C. Alley, Damon L. Meyer, Nicole M. Okeley, Svetlana O. Doronina, Charles G. Cerveny, Alan F. Wahl, Joseph A. Francisco and Brian E. Toki. Their work appears in journals such as Bioconjugate Chemistry, Cancer Research, Molecular Cancer Therapeutics, Blood and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.